Nurse Intervention Trial

Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Jan 8, 2024

Keywords

ClinConnect Summary

The Nurse Intervention Trial is studying how follow-up care for patients with certain types of headaches—like migraines and tension-type headaches—affects their treatment experience. The goal is to see if patients feel more satisfied and if they follow their treatment plan better when they receive follow-up phone calls from a headache nurse, compared to when they follow up on their own with their general doctor.

To participate, you need to be diagnosed with one of the specified headache types and be starting a preventive treatment that requires monitoring. The trial is open to adults aged 18 and older, regardless of gender. If you join, you will be randomly assigned to one of two groups: one will receive regular phone calls from a nurse to check in on your progress, while the other will be responsible for making follow-up appointments with their general doctor. This study is currently looking for participants, so if you or someone you know is dealing with these headaches, this could be a great opportunity to get extra support!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • One of the following headache diagnoses based on the International Classification of Headache Disorders, third edition (ICDH3): G44.2 Chronic tension-type headache and/or G43 Episodic and chronic migraine, G44.0 Episodic and chronic cluster headache, G44.8 Hemicrania Continua
• • Indication for preventive medication where there is at least one alternative with the need for follow-up assessment of effectiveness.
• Exclusion Criteria:
• • Uncertain headache diagnosis.
• • Need further investigation after the initial consultation.
• • Lack of understanding of information provided in Norwegian, both verbally and in writing.
• • Inability to keep a digital headache diary.
• • Need treatment of other comorbid conditions requiring follow-up in specialized healthcare.
• • Treatment with Onabotulinumtoxin A or Calcitonin-gene-related Peptide (CGRP) inhibitors given with three months intervals